CD4 antibody | YKIX302.9
Pacific Blue conjugated Mouse anti Canine CD4 antibody, clone YKIX302.9 (MCA1038PB) used for evaluation of CD4 expression on canine cells by flow cytometry.
Image caption:
CD11b+CD14−MHCII− cells suppress T cell proliferation. Facs sorted CD11b+CD14−MHCII− cells isolated from a dog with osteosarcoma or healthy PBMCs were co-incubated with mitogen-stimulated CD4+ and CD8+ T cells isolated from a healthy dog for 72 hrs. No stimulated cells were used as negative control. Proliferative responses were measured by 3H-thymidine incorporation from experiments performed in triplicate. CPM, counts per minute. Mean ± SEM are shown.
From: Goulart MR, Pluhar GE, Ohlfest JR (2012)
Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer.
PLoS ONE 7(3): e33274.
RPE conjugated Mouse anti Canine CD4 antibody, clone YKIC302.9
used for the assessment of CD4 levels on canine cells by flow cytometry.Image caption:
Immunophenotypic profile of tumor infiltrating lymphocyte in canine mammary carcinomas. Analysis of tumor infiltrating T-cells, B-lymphocytes and T-cell subsets from MC-BMT or MC (A), further subcategorized according to the absence (-) or presence (+) of lymph node metastasis (-) (B). Lymphocyte populations and subsets were identified by flow cytometric immunostaining as described in Material and Methods. Data were expressed as percentage of positive cells within gated lymphocytes and CD4+/CD8+ T-cell ratio. Significant differences at p < 0.05 are highlighted by asterisk.
From: From: Estrela-Lima et al.
BMC Cancer 2010 10:256.
FITC conjugated Mouse anti Canine CD4 antibody, clone YKIX302.9 (MCA1038F) used to evaluate CD4 expression on canine T-cell subsets by flow cytometry.
Image caption:
Representative dot plots illustrating the analysis of intracellular cytokine profile in T-cell subsets. (A) Pseudocolor plot distribution of short-term in vitro cultured (control or SLA-Ag stimulated) canine whole blood sample according to cell size (Forward scatter - FSC) and granularity (Side scatter- SSC) used for lymphocyte gate selection (R1) of FSCLowSSCLow events. (B) Pseudocolor plots representing cytokines + (IL-17, TNF-α, IFN-γ, TGF-β and IL-4) CD4+ cells within gated lymphocytes and (C) Pseudocolor plots representing cytokines + (IL-17, TNF-α, IFN-γ, TGF-β and IL-4) CD8+ cells within gated lymphocytes. The frequency of cytokines+ T-cells subsets were calculated by quadrant statistics approach and first reported as percentage of gated lymphocytes prior to the calculation of the SLAg/Control indexes.
From: Costa-Pereira C, Moreira ML, Soares RP, Marteleto BH, Ribeiro VM, França-Dias MH, Cardoso LM, Viana KF, Giunchetti RC, Martins-Filho OA, Araújo MS.
One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
BMC Vet Res. 2015 Apr 11;11:92.
FITC conjugated Rat anti Dog CD4 antibody, clone YKIX302.9 (MCA1038F) used for identifying CD4 expressing lymphocytes by flow cytometry.
Image caption:
Example gating scheme for identification of CD3+/CD4+ lymphocytes and CD21+ lymphocytes. Lymphocytes were identified and gated using a forward and side scatter plot (a). Gated lymphocytes were applied were then applied to PE (CD3) vs FITC (CD4) plots or an Alexa Fluor 647 (CD21) histogram, respectively. Unstained cells and matched isotype controls from the same manufacturer were used to determine cut offs for negative (b and d) versus positive (c and e) cells. CD3+/CD4+ or CD21 positive cells were then identified. CD3+/CD8+ cells were selected in the same manner as the CD3+/CD4+ cells
From: DeClue AE, Axiak-Bechtel SM, Zhang Y, Saha S, Zhang L, Tung DD, Bryan JN.
Identification of immunologic and clinical characteristics that predict
inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
BMC Vet Res. 2018 Apr 2;14(1):119.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rat anti Dog CD4:Alexa Fluor® 488
Rat anti Dog CD4:Alexa Fluor® 647
Rat anti Dog CD4:APC
Rat anti Dog CD4:FITC
Rat anti Dog CD4:Pacific Blue®
Rat anti Dog CD4
Rat anti Dog CD4:RPE
Rat anti Dog CD4:RPE-Cy7
- Product Type
- Monoclonal Antibody
- Clone
- YKIX302.9
- Isotype
- IgG2a
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA1038A488 | F | 100 Tests/1ml |
|
|
| MCA1038A647 | F | 100 Tests/1ml |
|
|
| MCA1038APC | F | 100 Tests |
|
|
| MCA1038F | F | 100 Tests |
|
|
| MCA1038PB | F | 100 Tests/1ml |
|
|
| MCA1038GA | C F | 0.1 mg |
|
|
| MCA1038PE | F | 100 Tests/1ml |
|
|
| MCA1038PECY7 | F | 100 Tests/1ml |
|
Rat anti Dog CD4 antibody, clone YKIX302.9, is a monoclonal antibody specific for the canine CD4 cell surface antigen. Clone YKIX302.9 was clustered at the first Canine Leukocyte Antigen Workshop (CLAW) [Cobbold et al. 1992] along with clone CA13.1E4.
Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered in vivo, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson et al. 1993).
Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocytes subsets Moore et al. 1992.
Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered in vivo, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson et al. 1993).
Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocytes subsets Moore et al. 1992.
Product Details
- Target Species
- Dog
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Allophycocyanin (APC) - lyophilised
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG conjugated to Pacific Blue® - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE)-Cy7 - lyophilised
- Reconstitution
- Reconstitute with 1.0 ml distilled water
- Reconstitution
- Reconstitute with 1.0 ml distilled water
- Reconstitution
- Reconstitute with 1ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. - Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose - Carrier Free
- Yes
- Immunogen
- Canine concanavilin A activated T cell blasts.
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. - Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of reconstitution.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 18 months from date of despatch.
- Guarantee
- 12 months from date of reconstitution.
- Guarantee
- 12 months from date of reconstitution
More Information
- UniProt
- P33705 Related reagents
- Entrez Gene
- CD4 Related reagents
- GO Terms
- GO:0007155 cell adhesion
- GO:0016021 integral to membrane
- GO:0006955 immune response
- GO:0045058 T cell selection
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- Cy® and CyDye® are registered trademarks of GE Healthcare
- Regulatory
- For research purposes only
Applications of CD4 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | 1/50 | 1/100 | |
| Immunohistology - Frozen | |||
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) | STAR131A | C E P WB | 1 ml |
|
|
| Goat anti Rat IgG:Biotin (Mouse Adsorbed) | STAR131B | C E IF P WB | 0.5 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:Dylight®800 | STAR16D800GA | F IF WB | 0.1 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:FITC | STAR17B | F | 1 mg |
|
|
| Rabbit F(ab')2 anti Rat IgG:HRP | STAR21B | C E P RE | 1 mg |
|
|
| Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) | STAR69 | F | 0.5 ml |
|
|
| Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) | STAR71D800GA | F IF WB | 0.1 mg |
|
|
| Goat anti Rat IgG:HRP (Mouse Adsorbed) | STAR72 | C E P | 0.5 mg |
|
|
| Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) | STAR73 | F | 0.5 ml |
|
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2a Negative Control:Alexa Fluor® 488 | MCA1212A488 | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:Alexa Fluor® 647 | MCA1212A647 | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:Alexa Fluor® 647 | MCA6005A647 | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:APC | MCA6005APC | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:FITC | MCA1212F | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:FITC | MCA6005F | F | 0.1 mg |
|
|
| Rat IgG2a Negative Control:Pacific Blue® | MCA1212PB | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:PacificBlue® | MCA6005PB | F | 100 Tests/1ml |
|
|
| Rat IgG2a Negative Control:RPE | MCA1212PE | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:RPE | MCA6005PE | F | 100 Tests |
|
|
| Rat IgG2a Negative Control:RPE-Cy7 | MCA6005PECY7 | F | 100 Tests/1ml |
|
Product Specific References
Source Reference
-
Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens. 43 (3): 137-54.
References for CD4 antibody
-
Schaut, R.G. et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
Vaccine. 34 (44): 5225-34. -
Gorman, S.D. et al. (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens.
Tissue Antigens. 43 (3): 184-8. -
Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
Br J Surg. 80 (11): 1389-92. -
Papadogiannakis, E.I. et al. (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture.
Can J Vet Res. 73 (2): 137-43. -
Bauer. T.R. Jr. et al. (2006) Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.
Blood. 108: 3313-20. -
Reis, A.B. et al. (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
Clin Exp Immunol. 146: 303-11. -
Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
Vet Immunol Immunopathol. 141: 64-75. -
Benyacoub, J. et al. (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs.
J Nutr. 133: 1158-62. -
Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
Cell Immunol. 263: 88-98. -
Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.
BMC Cancer. 10: 256. -
Out, T.A. et al. (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs.
Immunology. 105: 499-508. -
Boggiatto, P.M. et al. (2010) Immunologic indicators of clinical progression during canine Leishmania infantum infection.
Clin Vaccine Immunol. 17: 267-73. -
Mitchell, L. et al. (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
J Vet Intern Med. 26: 355-62. -
Tominaga, M. et al. (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
J Vet Diagn Invest. 22: 438-41. -
Figueiredo, M.M. et al. (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with Leishmania infantum.
Infect Immun. 82: 3704-12. -
Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
Vet Comp Oncol. 12: 29-36. -
Costa-Pereira, C. et al. (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
BMC Vet Res. 11 (1): 92. -
Hauck, V. et al. (2016) Increased numbers of FoxP3-expressing CD4(+) CD25(+) regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity.
Vet Dermatol. 27 (1): 26-e9. -
Riondato, F. et al. (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma.
Cytometry B Clin Cytom. Dec 13. [Epub ahead of print] -
Miranda, S. et al. (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
Vet Parasitol. 144 (3-4): 251-60. -
Yamaya, Y. & Watari, T. (2015) Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis.
J Vet Med Sci. 77 (4): 421-5. -
Schaut, R.G. et al. (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.
J Immunol. 196 (10): 4100-9. -
Tagawa, M. et al. (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.
PLoS One. 11 (2): e0150030. -
Munhoz, T.D. et al. (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy
Arq. Bras. Med. Vet. Zootec. 68 (1): 1-9. -
Miller, J. et al. (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism.
J Comp Pathol. 153 (1): 28-37. -
Duz AL et al. (2014) The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.
Mem Inst Oswaldo Cruz. 109 (8): 1005-13. -
Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
Vet Immunol Immunopathol. 159 (1-2): 91-6. -
Viana, K.F. et al. (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with Leishmania chagasi.
Vet Parasitol. 211 (3-4): 124-32. -
Viana, K.F. et al. (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
Parasit Vectors. 9: 250. -
Michael HT et al. (2013) Isolation and characterization of canine natural killer cells.
Vet Immunol Immunopathol. 155 (3): 211-7. -
Mitchell, L. et al. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.
Vet Immunol Immunopathol. 145 (3-4): 597-603. -
Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
Immunobiology. 221 (1): 12-22. -
Deravi, N. et al. (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
Vet Immunol Immunopathol. 191: 5-13. -
Bahamondes, F. et al. (2017) Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells.
BMC Vet Res. 13 (1): 166. -
Pinheiro, D. (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.
Immunology. 132: 111-22. -
Withers, S.S. et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.
Dev Comp Immunol. 87: 64-74. -
Declue, A.E. et al. (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
BMC Vet Res. 14 (1): 119. -
DaSilva, A.V.A. et al. (2018) Morphophysiological changes in the splenic extracellular matrix of Leishmania infantum-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens.
PLoS Negl Trop Dis. 12 (4): e0006445. -
Roatt, B.M. et al. (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden.
Front Immunol. 8: 217.
